CYX Calyx Ventures Inc

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


Calyx Bio-Ventures Inc. ("Calyx" or the "Company") (TSX VENTURE:CYX) announces
that, effective today, it closed the remainder of the non-brokered private
placement (the "Second Closing") first announced on June 25, 2013 and further
increased on July 3, 2013 (the "Financing"). The Second Closing consisted of the
sale of 1,466,666 units (the "Units) at a price of $0.15 per Unit for gross
proceeds of $220,000. A first closing of the Financing took place on July 4,
2013 (the "First Closing), and consisted of the sale of 3,763,334 Units for
gross proceeds of $564,500. In aggregate between the first and second closing of
the Financing, the Company sold 5,230,000 Units for gross proceeds of $784,500.


Each Unit comprises one common share of the Company and one common share
purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable
into one common share of the Company for a period of 18 months from closing at
an exercise price of $0.35.


In connection with the Second Closing, the Company paid finders fees of $17,600
and issued 117,333 brokers' warrants (the "Brokers' Warrants). Each Brokers'
Warrant is exercisable into one common share of the Company for a period of 18
months from closing at an exercise price of $0.35. In connection with the First
Closing, the Company paid finders fees of $44,720 and issued 171,467 Brokers'
Warrants. In aggregate between the first and second closing of the Financing,
the Company paid total finders fees of $62,320 and issued 288,800 Brokers'
Warrants.


The funds raised from the Financing will be used general working capital purposes.

The securities issued pursuant to the Financing will be subject to a standard
four month hold period.


About Calyx

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company
focused on renewable fuels including biojet and biodiesel. Calyx's operating
subsidiary, Agrisoma Biosciences Inc., is producing a new proprietary non-food
energy feedstock crop, Resonance(R) carinata, which yields oil that can be
refined into fuels that work in existing engines as a 100 percent petroleum
substitute. From seed to sky, fuels produced from Resonance(R) carinata
substantially reduce carbon and other harmful emissions, and help to reduce
global petroleum dependence. For further information about Calyx, please visit
www.calyxbio.com. Resonance(R) is a registered trademark of Agrisoma Biosciences
Inc.


Forward-Looking Statements: This document contains certain forward-looking
statements concerning Calyx, as well as other expectations, plans, goals,
objectives, information or statements about future events, conditions, or
performance that may constitute "forward-looking statements" or "forward-looking
information" under applicable securities legislation. Such statements or
information involve substantial known and unknown risks and uncertainties,
certain of which are beyond Calyx's control, including the completion of the
Private Placement and the delay or failure to receive regulatory approvals., 


Such forward-looking statements or information are based on a number of
assumptions, which may prove to be incorrect. In addition to other assumptions
identified in this news release, assumptions have been made regarding, among
other things, timing and completion of the Private Placement, the actual use of
proceeds, and the timing of receipt of regulatory approvals. 


Although Calyx believes that the expectations reflected in such forward-looking
statements or information are reasonable, undue reliance should not be placed on
forward-looking statements because Calyx can give no assurance that such
expectations will prove to be correct. Forward-looking statements or information
are based on current expectations, estimates and projections that involve a
number of risks and uncertainties which could cause actual results to differ
materially from those anticipated by Calyx and described in the forward-looking
statements or information.


The forward-looking statements or information contained in this news release are
made as of the date hereof and Calyx undertakes no obligation to update publicly
or revise any forward-looking statements or information, whether as a result of
new information, future events or otherwise unless so required by applicable
securities laws or the TSX Venture Exchange. The forward-looking statements or
information contained in this news release are expressly qualified by this
cautionary statement.


This press release shall not constitute an offer to sell, nor the solicitation
of an offer to buy, any securities in the United States, nor shall there be any
sale of securities mentioned in this press release in any state in the United
States in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
W. Hugh Notman
President & CEO
604-689-2495
hnotman@calyxbio.com


Investor Relations:
Keir Reynolds
778-998-9242
kreynolds@calyxbio.com

Grafico Azioni Calyx Ventures (TSXV:CYX)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Calyx Ventures (TSXV:CYX)
Storico
Da Giu 2023 a Giu 2024